Completed NA INTERVENTIONAL 1-arm NCT01781117

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)

Sponsor: KYU-SUNG LEE

Conditions Benign Prostatic Hypertrophy With Outflow Obstruction Overactive Detrusor

Interventions Holmium Laser Enucleation of the Prostate (HoLEP) Holmium laser enucleation system and morcellator

Updated 7 times since 2017 Last updated: Nov 28, 2019 Started: Feb 28, 2013 Primary completion: Nov 30, 2016 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01781117, this NA trial focuses on Benign Prostatic Hypertrophy With Outflow Obstruction and Overactive Detrusor and remains completed. Sponsored by KYU-SUNG LEE, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jan 2020 — Jan 2021 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Jun 2018 — Jan 2020 [monthly]

Unknown Status NA
Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KYU-SUNG LEE
Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea